VANCOUVER, BC July 22, 2016 - Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) today announced Ann Fehr is joining the growing specialty pharmaceutical company as its new Chief Financial Officer (CFO) effective July 22, 2016. Ms. Fehr brings to Aequus over 20 years of management experience in corporate finance, treasury, financial planning and analysis, tax, and risk management in a number of rapidly growing entrepreneurial companies.
“We are very fortunate to have Ann join Aequus. Ann’s depth of experience in senior financial positions with high growth companies is ideal for Aequus as we continue to expand our commercial efforts in Canada and advance our development programs,” said Doug Janzen, Chairman and CEO of Aequus. “Over the past year, we have evolved into a revenue-generating entity and have expanded our internal team through the acquisition of TeOra Health to foster this growth strategy. Ann’s diverse background and expertise will further enhance Aequus’ current management team as we continue to build value for our shareholders.”
Ms. Fehr is the Principal at Fehr & Associates, and has held a number of senior level positions including having served as CFO of Carrus Capital Corporation (formerly BioWest Therapeutic Inc.), Global Minerals Ltd., and other companies listed on the TSX. During the course of her management and consulting career, Ms. Fehr has led a number of companies through significant change and corporate milestones such as public listing applications, mergers and acquisitions, as well as strategic planning and execution. Ms. Fehr is also an active volunteer in the community. Since 2013, she has been Treasurer and a Director for the Boys and Girls Clubs of South Coast BC.
“I can’t imagine a more exciting time to join Aequus,” Ms. Fehr said. “I look forward to working with the Aequus team to ensure we are financially well positioned for success.”
The Company also announces that Ms. Christina Yip will no longer be part of Aequus’ management team. “We would like to thank Christina for her substantial contributions and dedication during her time at Aequus, particularly for instilling a fiscal discipline that leaves us well positioned for the future,” said Mr. Janzen. “We wish Christina all the best in her future endeavours.”
Aequus is also pleased to announce it has granted incentive stock options to a consultant and officer of the Company for the right to purchase up to an aggregate of 150,000 common shares of the Company. These stock options are exercisable at a price of $0.34 per share, for a term of eight years, and vest in tranches over a 3 year period. The terms of the stock options granted on July 22, 2016 are in accordance with the Company’s Stock Option Plan.
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a Vancouver-based, specialty pharmaceutical company primarily focused on developing and commercializing high quality, differentiated products. Aequus’ development stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada and to establish strategic partnerships to accelerate product development and maximize the reach of its product candidates worldwide. Aequus also has a Canadian commercial platform to build on for the launch of products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.